Actively Recruiting
Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
Led by Beijing Tiantan Hospital · Updated on 2026-01-02
4000
Participants Needed
1
Research Sites
125 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.
CONDITIONS
Official Title
Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of screening
- Patients with non-cardioembolic ischemic stroke or transient ischemic attack within 3 months before screening
- Prescribed Evolocumab as decided by their physician
- Signed informed consent to participate in the study
You will not qualify if you...
- History of intracranial hemorrhagic diseases such as cerebral hemorrhage or subarachnoid hemorrhage
- Presence of hemorrhage or other brain diseases like vascular malformations, tumors, abscesses, or multiple sclerosis confirmed by head CT or MRI
- Silent cerebral infarction without symptoms
- Participation in another drug or device clinical trial within the past 3 months or ongoing at screening
- Use of Evolocumab or other PCSK9 inhibitors within 6 months before screening
- Expected life span less than 12 months or inability to complete the study
- Mental, cognitive, or emotional disorders preventing understanding or following study procedures
- Refusal to participate in the enrollment survey
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital
Beijing, China
Actively Recruiting
Research Team
J
Jie Xu
CONTACT
A
Aichun Cheng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here